Approximately 5,000 people in the U.S. develop amyotrophic lateral sclerosis (ALS) each year. On average, they survive for ...
On the heels of its most advanced medicine flunking a key study, the drugmaker is looking at the different paths it could ...
Approximately 5,000 people in the U.S. develop amyotrophic lateral sclerosis (ALS) each year. On average, they survive for only two to five years ...
This November, the nonprofit I AM ALS is launching a peer support program as part of its new campaign focused on supporting ...
The University of Ghana (UG), in collaboration with Google Research Africa and the University College of London’s (UCL) ...
Neurosense Therapeutics (NASDAQ:NRSN) is developing novel treatments for neurodegenerative diseases like amyotrophic lateral ...
In September 2024, Athira announced topline results from the LIFT-AD Phase 2/3 clinical trial of fosgonimeton in mild-to-moderate Alzheimer’s disease. The study did not meet its primary or key ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback